Baili Tianheng announced that Pangu Capital, a wholly-owned subsidiary, plans to subscribe for 3881,000 Series A preferred shares of Connexus Therapeutics with 5 million US dollars in cash and hold 7.91% of Connexus Therapeutics' shares after the capital increase is completed. This transaction constitutes a related transaction. It was reviewed and approved by a special meeting of the board of directors and independent directors on September 16, 2026, and there is no need to submit it to the shareholders' meeting for review.

Baili Tianheng announced that Pangu Capital, a wholly-owned subsidiary, plans to subscribe for 3881,000 Series A preferred shares of Connexus Therapeutics with 5 million US dollars in cash and hold 7.91% of Connexus Therapeutics' shares after the capital increase is completed. This transaction constitutes a related transaction. It was reviewed and approved by a special meeting of the board of directors and independent directors on September 16, 2026, and there is no need to submit it to the shareholders' meeting for review.